Advertisement
Advertisement
SEPN
Septerna, Inc. Common Stock
47.88
USDSponsored
+4.18
+9.57%
Nov 04, 15:59 UTC -5
Closed
Pre-Market
48.30
+0.42
+0.88%
Septerna, Inc. Common Stock (SEPN) Earnings
SEPN Earnings Reports
Positive Surprise Ratio
SEPN beat 4 of 7 last estimates.
57%
Next Report
Date of Next Report
Nov 25, 2026
Estimate for Q3 26 (Revenue/ EPS)
$21.20M
/-$0.42
Implied change from Q2 26 (Revenue/ EPS)
-20.75%
/+50.00%
Implied change from Q3 25 (Revenue/ EPS)
-1.39%
/+366.67%
Septerna, Inc. Common Stock earnings per share and revenue
On Aug 10, 2026, SEPN reported earnings of -0.28 USD per share (EPS) for Q2 26, beating the estimate of -0.43 USD, resulting in a 33.26% surprise. Revenue reached 26.75 million, compared to an expected 18.23 million, with a 46.69% difference. The market reacted with a +22.93% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 9 analysts forecast an EPS of -0.42 USD, with revenue projected to reach 21.20 million USD, implying an increase of 50.00% EPS, and decrease of -20.75% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Cytokinetics Inc.
Report Date
Nov 04, 2026 For Q3 26
Estimate
-$1.48
Actual
-$1.37
Surprise
+7.82%
Arcutis Biotherapeutics, Inc. Common Stock
Report Date
Nov 04, 2026 For Q3 26
Estimate
$0.16
Actual
$0.06
Surprise
-64.54%
Viridian Therapeutics, Inc. Common Stock
Report Date
Nov 04, 2026 For Q3 26
Estimate
-$0.98
Actual
-$0.81
Surprise
+18.04%
Harmony Biosciences Holdings, Inc. Common Stock
Report Date
Nov 04, 2026 For Q3 26
Estimate
$1.15
Actual
$0.81
Surprise
-30.03%
Vir Biotechnology, Inc. Common Stock
Report Date
Nov 04, 2026 For Q3 26
Estimate
-$0.76
Actual
-$0.56
Surprise
+25.20%
Revolution Medicines, Inc. Common Stock
Report Date
Nov 04, 2026 For Q3 26
Estimate
-$2.46
Actual
-$1.90
Surprise
+22.81%
Bio-Rad Laboratories, Inc. Class B
Report Date
Nov 04, 2026 For Q3 26
Estimate
$2.24
Actual
$2.65
Surprise
+17.92%
Nuvation Bio Inc.
Report Date
Nov 04, 2026 For Q3 26
Estimate
-$0.12
Actual
-$0.12
Surprise
+4.15%
Myriad Genetics Inc
Report Date
Nov 04, 2026 For Q3 26
Estimate
-$0.20
Actual
-$0.11
Surprise
+46.08%
Nuvectis Pharma, Inc. Common Stock
Report Date
Nov 04, 2026 For Q3 26
Estimate
-$0.24
Actual
-$1.02
Surprise
-313.79%
FAQ
What were Septerna, Inc. Common Stock's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Septerna, Inc. Common Stock reported EPS of -$0.28, beating estimates by 33.26%, and revenue of $26.75M, 46.69% above expectations.
How did the market react to Septerna, Inc. Common Stock's Q2 2026 earnings?
The stock price moved up 22.93%, changed from $38.85 before the earnings release to $47.76 the day after.
When is Septerna, Inc. Common Stock expected to report next?
The next earning report is scheduled for Nov 25, 2026.
What are the forecasts for Septerna, Inc. Common Stock's next earnings report?
Based on 9
analysts, Septerna, Inc. Common Stock is expected to report EPS of -$0.42 and revenue of $21.20M for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.